Kymera Therapeutics downgraded to Neutral from Outperform at Credit Suisse
The Fly

Kymera Therapeutics downgraded to Neutral from Outperform at Credit Suisse

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App